PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmcimmBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Immunology
 
BMC Immunol. 2012; 13: 34.
Published online Jul 6, 2012. doi:  10.1186/1471-2172-13-34
PMCID: PMC3472185
Synthesized OVA323-339MAP octamers mitigate OVA-induced airway inflammation by regulating Foxp3 T regulatory cells
Wen Su,#1 Wenwei Zhong,#1 Yanjie Zhang,1 and Zhenwei Xiacorresponding author1,2
1Department of Pediatrics, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
2Department of Pediatrics, Ruijin Hospital, Ruijin 2nd Road 197, Shanghai, 200025, China
corresponding authorCorresponding author.
#Contributed equally.
Wen Su: rebecca312/at/hotmail.com; Wenwei Zhong: zhwwgzf/at/hotmail.com; Yanjie Zhang: jenny2049/at/163.com; Zhenwei Xia: xzw63/at/hotmail.com
Received January 19, 2012; Accepted June 27, 2012.
Abstract
Background
Antigen-specific immunotherapy (SIT) has been widely practiced in treating allergic diseases such as asthma. However, this therapy may induce a series of allergic adverse events during treatment. Peptide immunotherapy (PIT) was explored to overcome these disadvantages. We confirmed that multiple antigen peptides (MAPs) do not cause autoimmune responses, which led to the presumption that MAPs intervention could alleviate allergic airway inflammation without inducing adverse effects.
Results
In this study, synthesized OVA323-339MAP octamers were subcutaneously injected into ovalbumin (OVA)-sensitized and -challenged Balb/c mice to observe its effect on allergic airway inflammation, Th2 immune response, and immune regulating function. It was confirmed that OVA sensitization and challenge led to significant peritracheal inflammatory, cell infiltration, and intensive Th2 response. Treatment of OVA323-339MAP octomers in the airway inflammation mice model increased CD4+CD25+Foxp3+ T regulatory (Treg) cells and their regulatory function in peripheral blood, mediastinal draining lymph nodes, and the spleen. Furthermore, OVA323-339MAP increased IL-10 levels in bronchial alveolar lavage fluid (BALF); up-regulated the expression of IL-10, membrane-bound TGF-β1, as well as Foxp3 in lung tissues; and up-regulated programmed death-1 (PD-1) and cytotoxic T lymphocyte associated antigen 4 (CTLA-4) on the surface of Treg cells. These results were further correlated with the decreased OVA specific immunoglobulin E (sIgE) level and the infiltration of inflammatory cells such as eosinophils and lymphocytes in BALF. However, OVA323-339 peptide monomers did not show any of the mentioned effects in the same animal model.
Conclusions
Our study indicates that OVA323-339MAP had significant therapeutic effects on mice allergic airway inflammation by regulating the balance of Th1/Th2 response through Treg cells in vivo.
Keywords: Allergic airway inflammation, Specific immunotherapy, Multiple antigen peptide
Articles from BMC Immunology are provided here courtesy of
BioMed Central